Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SA3Ag vaccine · 1 trial · 5 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | SA3Ag in both stage 1 and stage 2 |
| 2 | EXPERIMENTAL | SA3Ag in stage 1 followed by placebo in stage 2. |
| 3 | PLACEBO_COMPARATOR | Placebo in both stage 1 and stage 2 |
| 4 | EXPERIMENTAL | SA3Ag in stage 1 and no vaccine in stage 2. |
| 5 | PLACEBO_COMPARATOR | Placebo in stage 1 and no vaccine in stage 2. |
| Name | Type | Description |
|---|---|---|
| SA3Ag vaccine | BIOLOGICAL | In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses: Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1. |
| Blood draw | PROCEDURE | Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1. |
| Colonization swab samples | PROCEDURE | Colonization swabs will be taken at timepoints throughout stage 1 and stage 2. |
| SA3Ag followed by Placebo | BIOLOGICAL | In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses: Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo. |
| Placebo | BIOLOGICAL | In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study. |
| SA3Ag with no booster in stage 2 | BIOLOGICAL | In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses: Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm In stage 2 the subject will receive no vaccine. |
| Placebo with no booster in stage 2 | PROCEDURE | In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl. In stage 2 the subject will receive no vaccine. |
Inclusion Criteria: * Healthy adults aged 18 to 24 years or 50 to 85 years who are available for the entire duration of the study, able to be contacted by phone, and able to complete all study procedures, including completion of an electronic diary (e-diary). * Men and women who are able to have ch...
Top 20 of 28 competitors
SA3Ag vaccine is an investigational 3-antigen Staphylococcus aureus vaccine being developed for the prevention of bacterial infections, specifically staphylococcal infections. It is designed to elicit an immune response against Staphylococcus aureus. The vaccine is currently in clinical development and has not been approved by regulatory authorities.
SA3Ag vaccine is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical trials to evaluate the safety and immunogenicity of this investigational vaccine in healthy adults.
SA3Ag vaccine is in Phase 1 clinical development. It has completed a Phase 1 trial that evaluated three dose levels of the vaccine in healthy adults. The vaccine remains investigational and has not received regulatory approval for any indication.
SA3Ag vaccine has one completed clinical trial registered as NCT01018641, titled "An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults." This Phase 1 trial enrolled 449 participants in Australia and was a randomized, double-blind, placebo-controlled study.
SA3Ag vaccine is a 3-antigen Staphylococcus aureus vaccine, meaning it contains three antigens from the bacterium Staphylococcus aureus. It is being studied for its potential to prevent staphylococcal infections, including skin infections. The vaccine is distinct from other staphylococcal vaccines due to its specific antigen composition.